Rxwire
In the news · 48h FDA 39 Eli Lilly 19 Roche 9 Merck & Co. (MSD) 8 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Novo Nordisk 3
Approvals & regulatory · first seen yesterday, updated yesterday

Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

1 outlet FDA

FDA Clearance and CE Mark Complete Aptiva's Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Werfen today announced that its Aptiva Antiphospholipid Syndrome…

Summary from PR Newswire - FDA Approval.

Coverage 1 article · 1 outlet

  1. PR Newswire - FDA Approval
    Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent